Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Share-based Compensation (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Share-based Compensation for 8 consecutive years, with $881150.0 as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 76.01% to $881150.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $13.1 million, a 129.34% increase, with the full-year FY2025 number at $8.9 million, up 64.53% from a year prior.
  • Share-based Compensation was $881150.0 for Q4 2025 at Outlook Therapeutics, down from $6.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.8 million in Q3 2025 to a low of $881150.0 in Q4 2025.